Form 4: STAAR SURGICAL CDO Michna Reports Equity Vesting

STAAR SURGICAL's Chief Development Officer, Magda Michna, reported the vesting of restricted stock units and subsequent tax-related share disposals.

Summary

• Magda Michna, Chief Development Officer of STAAR SURGICAL CO, reported multiple equity transactions.
• On March 12, 2026, 6,178 shares of common stock vested from Restricted Stock Units (RSUs) granted on March 12, 2024.
• On March 12, 2026, 2,216 shares were withheld to satisfy taxes at a price of $18.39 per share.
• On March 13, 2026, 33,838 new Restricted Stock Units were granted as part of an annual equity award, scheduled to vest in thirds from March 2027 to March 2029.
• On March 14, 2026, a total of 17,595 shares (14,663 + 2,932) of common stock vested from RSUs granted on March 14, 2025.
• On March 14, 2026, a total of 6,313 shares (5,261 + 1,052) were withheld to satisfy taxes at a price of $18.84 per share.
• Following these transactions, Magda Michna beneficially owns 29,668 direct shares, which includes previously granted RSUs subject to future vesting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting routine executive compensation and continued alignment of management's interests with the company's long-term performance through new equity grants and vesting shares.

Positives

• Chief Development Officer Magda Michna received a new annual equity award of 33,838 Restricted Stock Units, demonstrating continued incentive alignment with company performance.
• Significant portions of previously granted Restricted Stock Units vested, converting into common stock and increasing the officer's direct ownership.

Negatives

• A total of 8,529 shares (2,216 + 6,313) were disposed of to cover tax obligations, representing a reduction in direct share ownership from vested units.

Risks

• The value of the vested shares and future RSU grants is subject to market fluctuations of STAAR SURGICAL CO common stock.

Future Outlook

The Chief Development Officer has significant future equity incentives, with 33,838 new Restricted Stock Units granted on March 13, 2026, scheduled to vest in annual installments through March 2029. Additionally, previously granted RSUs will continue to vest through March 2028, aligning management's long-term interests with shareholder value.

Management Comments

• The reporting person's signature confirms the accuracy of the reported transactions.

Industry Context

StockSavvy.ai notes that the regular vesting of Restricted Stock Units and the granting of new annual equity awards are standard practices in the biotechnology and medical device industries, such as STAAR SURGICAL operates in. This compensation structure is designed to retain key talent and align executive incentives with long-term company performance and shareholder returns, a common strategy for growth-oriented companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a widely adopted practice across the technology and healthcare sectors, including companies like Abbott Laboratories and Johnson & Johnson, which also utilize performance-based equity awards to incentivize long-term value creation.
• The vesting schedule over multiple years is consistent with industry benchmarks for executive retention and alignment.

Stakeholder Impact

• Shareholders: The vesting and new RSU grants align the Chief Development Officer's interests with shareholders, potentially encouraging long-term value creation. The tax-related share sales are a minor dilution event but are standard.
• Employees: The equity compensation structure for a key executive may signal a stable and competitive compensation framework within the company.

Next Steps

• 6,178 shares from the March 12, 2024 RSU grant will vest on March 12, 2027.
• 11,279 shares from the March 13, 2026 RSU grant will vest on March 13, 2027.
• 14,663 shares from the March 14, 2025 RSU grant will vest on March 14, 2027.
• 2,933 shares from the March 14, 2025 RSU grant will vest on March 14, 2027.
• Further RSU vesting events are scheduled for March 13, 2028, March 14, 2028, and March 13, 2029.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation events for a key executive, including RSU vesting and new grants. These transactions are expected and do not indicate any fundamental change in the company's operations or outlook. While the new RSU grant is a positive for executive alignment, the overall impact on the company's valuation or strategic direction is neutral. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

STAAR SURGICAL, STAA, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Development Officer, Magda Michna, Insider Ownership